Bicara Therapeutics (BCAX) Cash from Investing Activities (2023 - 2026)

Bicara Therapeutics' Cash from Investing Activities history runs 4 years deep, the most recent figure standing at $100.9 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities changed N/A year-over-year to $100.9 million in Q1 2026; TTM through Mar 2026 was -$217.5 million, a 324546.27% decrease from a year earlier, with the FY2025 full-year figure at -$318.5 million, down 3538266.67% from the prior year.
• Cash from Investing Activities rose to $100.9 million in Q1 2026 per BCAX's latest filing, from -$82.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $100.9 million in Q1 2026 and bottomed at -$236.1 million in Q3 2025.
• The 4-year median for Cash from Investing Activities is -$29500.0 (2024), against an average of -$27.2 million.
• Across the five-year window, Cash from Investing Activities jumped 90.83% in 2024 and sank 2951412.5% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$436000.0 in 2023, then soared by 90.83% to -$40000.0 in 2024, then tumbled by 205730.0% to -$82.3 million in 2025, then soared by 222.6% to $100.9 million in 2026.
• Per Business Quant, the three latest BCAX Cash from Investing Activities figures stand at $100.9 million (Q1 2026), -$82.3 million (Q4 2025), and -$236.1 million (Q3 2025).